Think-tank says "UN is making AIDS worse"

11 December 2006

The United Nations was accused, on World AIDS Day, of worsening the HIV/AIDS problem by a catalog of strategic errors, according to the International Policy Network, a London, UK-based think-tank. Philip Stevens, the group's health program director, criticized the UN and the World Health Organization's alleged "abject failure" to cope with the problem.

Mr Stevens said that, "since 2000, the UN has focused myopically on treating those already infected, while ignoring the vital task of prevention. As a direct result, the total number of infected people continues to grow." The UN's AIDS organization (UNAIDS) only decided to shift resources to prevention in August this year, according to the IPN. Mr Stevens asked: "why has no one in UNAIDS been held accountable for this gross strategic error?"

The problem of untested triple combination antiretroviral drugs, which were withdrawn in 2004 by the WHO, was the emergence of drug-resistant strains of HIV/AIDS, particularly in Thailand, Mr Stevens said. He predicted that, "as more and more patients in poor countries develop drug resistance, the astronomical cost of putting millions of patients on second-line treatments could bankrupt entire health care systems."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight